<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Approximately 795,000 people experience a new or recurrent <z:hpo ids='HP_0001297'>stroke</z:hpo> in the United States annually </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of this study was to assess the protective effect of a nonselective opioid receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>, biphalin, in <z:hpo ids='HP_0002181'>brain edema</z:hpo> and <z:mpath ids='MPATH_124'>infarct</z:mpath> damage by using both in vitro and in vivo models of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In an in vivo model of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, biphalin significantly decreased <z:hpo ids='HP_0000969'>edema</z:hpo> (66.6 and 58.3%) and <z:mpath ids='MPATH_124'>infarct</z:mpath> (52.2 and 56.4%) ratios in mouse transient (60-min occlusion/24-h reperfusion) and permanent (6 h) middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> models, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Biphalin administration also showed decreased <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> in hippocampal, cortical, and striatal brain tissue after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, evidenced by reduced Fluoro-Jade C staining </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, biphalin improved neurological function after <z:hpo ids='HP_0001297'>stroke</z:hpo> injury evidenced by neurological score and locomotor activity evaluation </plain></SENT>
<SENT sid="5" pm="."><plain>Biphalin significantly decreased penumbral expression of <z:chebi fb="0" ids="29101">Na(+)</z:chebi>, <z:chebi fb="0" ids="29103">K(+)</z:chebi>, 2Cl(-) cotransporter (NKCC) and the translocation of the conventional isoforms of protein kinase C (PKC) </plain></SENT>
<SENT sid="6" pm="."><plain>It also reversed the activation of PKC-induced cell volume increase during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in primary neuronal cell cultures exposed to 1 h of oxygen <z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation </plain></SENT>
<SENT sid="7" pm="."><plain>These data suggest that opioid receptor activation provides neuroprotection during <z:hpo ids='HP_0001297'>stroke</z:hpo>, and a possible explanation of this mechanism could be the inhibition of NKCC function via the regulation of PKC-dependent cell signaling </plain></SENT>
</text></document>